SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS
Clinical trials for SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS explained in plain language.
Never miss a new study
Get alerted when new SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS trials appear
Sign up with your email to follow new studies for SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New injection shows promise for dialysis patients with hormone imbalance
Disease control CompletedThis study tested a new injection called MT1013 in 115 adults with chronic kidney disease who are on dialysis and have secondary hyperparathyroidism (overactive parathyroid glands). The goal was to see if the drug could safely lower high parathyroid hormone levels by at least 30%…
Matched conditions: SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS
Phase: PHASE2 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 12:07 UTC
-
New drug shows promise for dialysis patients with hormone imbalance
Disease control CompletedThis study tested a new drug called MT1013 in 98 adults on hemodialysis who have secondary hyperparathyroidism, a condition where parathyroid hormone levels are too high. The goal was to see if the drug is safe and can lower hormone levels. Participants received either the drug o…
Matched conditions: SECONDARY HYPERPARATHYROIDISM (SHPT) IN SUBJECTS WITH CHRONIC KIDNEY DISEASE (CKD) ON HEMODIALYSIS
Phase: PHASE2 • Sponsor: Shaanxi Micot Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 12:04 UTC